CYTOMX THERAPEUTICS INC (CTMX) Stock News

USA - NASDAQ:CTMX - US23284F1057 - Common Stock

3.33 USD

+0.07 (+2.15%)

Last: 10/30/2025, 8:01:13 PM

3.39 USD

+0.06 (+1.8%)

Pre-Market: 10/31/2025, 8:23:33 AM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

CTMX Latest News, Press Relases and Analysis

All

Press Releases

a day ago - By: CytomX Therapeutics Inc.

CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025

10 days ago - By: Benzinga

CytomX Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

11 days ago - By: CytomX Therapeutics Inc.

CytomX Therapeutics Appoints Rachael Lester as Chief Business Officer

a month ago - By: The Motley Fool

Why CytomX Therapeutics Stock Was Skyrocketing This Week

a month ago - By: Benzinga - Mentions: XRTX DRIO MTNB ORGO ...

12 Health Care Stocks Moving In Thursday's After-Market Session

3 months ago - By: The Motley Fool

CytomX (CTMX) Q2 Revenue Drops 26%

3 months ago - By: Zacks Investment Research - Mentions: OCS

CytomX Therapeutics (CTMX) Reports Break-Even Earnings for Q2

3 months ago - By: CytomX Therapeutics Inc.

CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update

3 months ago - By: CytomX Therapeutics Inc.

CytomX Therapeutics to Report Second Quarter 2025 Financial Results on August 7, 2025

5 months ago - By: CytomX Therapeutics Inc.

CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference

6 months ago - By: CytomX Therapeutics Inc.

CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Melanoma

6 months ago - By: Stocktwits

CytomX Stock Hits 2-Month High After Upbeat Q1 Earnings, Promising Early Data For Cancer Drug

6 months ago - By: Zacks Investment Research - Mentions: SEER

CytomX Therapeutics (CTMX) Beats Q1 Earnings and Revenue Estimates

6 months ago - By: CytomX Therapeutics Inc.

CytomX Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock

6 months ago - By: CytomX Therapeutics Inc.

CytomX Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

6 months ago - By: CytomX Therapeutics Inc.

CytomX Announces Positive Interim Data From Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) Candidate in Patients with Advanced Colorectal Cancer (CRC)